Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Heart Failure NYHA Class IV Clear all
Recruiting Not applicable Interventional

Sustaining Home Heart Failure Palliative Care in Rural Appalachia

NCT06791850
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
HF-FamPALhomeCARE
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
45 Years to 80 Years
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure

NCT00853658
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
Enalapril, Aliskiren
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7,064 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
58
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Jul 21, 2026, 10:24 PM EDT
Active, not recruiting Not applicable Interventional

An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure

NCT06859970
View directory record Official record
Conditions
Heart Failure, Heart Failure NYHA Class III, Heart Failure With Reduced Ejection Fraction, Ambulatory Heart Failure, NYHA Class IV
Interventions
PAS-C System
Device
Lead sponsor
InterShunt Technologies, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
6
States / cities
Jonesboro, Arkansas • Thousand Oaks, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device

NCT00957541
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Paradym CRT + Physiological Diagnosis (PhD)
Device
Lead sponsor
ELA Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Jul 21, 2026, 10:24 PM EDT
Not listed Not applicable Interventional

Feasibility Study of the Intravascular Ventricular Assist System (iVAS)

NCT02645539
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
intravascular ventricular assist system (iVAS)
Device
Lead sponsor
NuPulseCV
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
18
States / cities
Washington D.C., District of Columbia • Orlando, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Hemodynamic-GUIDEd Management of Heart Failure

NCT03387813
View directory record Official record
Conditions
Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
Interventions
CardioMEMS™ HF System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
125
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

Warfarin and Antiplatelet Therapy in Chronic Heart Failure

NCT00007683
View directory record Official record
Conditions
Heart Failure
Interventions
Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
79
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Study of Default Options in Advance Directives

NCT01817686
View directory record Official record
Conditions
COPD, Severe or Very Severe Airflow Obstruction and/or Receiving or Eligible to Receive Long-term Oxygen Therapy, Idiopathic Pulmonary Fibrosis, Other Interstitial Lung Disease Without Curative Therapy, Congestive Heart Failure, NYHA Class IV or NYHA Class III Plus 1 Hospitalization in the Past Year, Malignancy, Any Stage 3B or 4 Solid Tumor
Interventions
Comfort Default AD forms, Life Extension Default AD forms, Standard Default AD forms
Other
Lead sponsor
Corporal Michael J. Crescenz VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

NCT01920711
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
LCZ696, Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
4,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
110
States / cities
Huntsville, Alabama • Mobile, Alabama • Muscle Shoals, Alabama + 92 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Addressing Pain Through Navigator-Led Palliative Care Optimized for Heart Failure (ADAPT-HF)

NCT06270875
View directory record Official record
Conditions
Chronic Illness, NYHA Class II-IV Heart Failure
Interventions
ADAPT HF
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Completed No phase listed Observational

Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management

NCT01452802
View directory record Official record
Conditions
Heart Failure
Interventions
HM II (HeartMate II LVAD), OMM (Optimal Medical Management)
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 85 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
52
States / cities
Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 2 Interventional

Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure

NCT01814319
View directory record Official record
Conditions
Systolic Heart Failure
Interventions
Probenecid 1 gr oral twice daily, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2015 · Synced Jul 21, 2026, 10:24 PM EDT
Recruiting Phase 1 Interventional

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

NCT05647213
View directory record Official record
Conditions
Univentricular Heart, Congenital Heart Disease, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
iPSC-CL
Biological
Lead sponsor
HeartWorks, Inc.
Other
Eligibility
18 Years to 40 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 21, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional

ZP120 Add-on to Furosemide in Treatment of Acute or Sub-Acute Decompensated Heart Failure

NCT00283361
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
ZP120, I.v. catherization, 6-minutes walk performance, Dyspnea severity assessment, Blood sampling for laboratory tests, ECG, Physical examination
Drug · Procedure · Behavioral
Lead sponsor
Zealand Pharma
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
22
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2007 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

Family Palliative and End-of-Life Care for Advanced Heart Failure

NCT04153890
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
FamPALcare
Behavioral
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Phase 3 Interventional

THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation

NCT00578695
View directory record Official record
Conditions
Hyponatremia
Interventions
lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Bakersfield, California + 82 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional

Exergaming in Advanced HF With Multiple Chronic Conditions Prior to LVAD Implantation or Heart Transplant

NCT03580759
View directory record Official record
Conditions
Heart-Assist Devices, Heart Failure NYHA Class IV, Exercise Training
Interventions
PREHAB
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 21, 2026, 10:24 PM EDT
Terminated Phase 2 Interventional

Study of DITPA in Patients With Congestive Heart Failure

NCT00103519
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
DITPA (3,5-diiodothyropropionic acid), Placebo
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
22
States / cities
Huntsville, Alabama • Peoria, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Not applicable Interventional Results available

A Study to Improve Physician-Youth Communication and Medical Decision Making

NCT05835063
View directory record Official record
Conditions
Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
We Chatt communication tool, Usual/standard care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
12 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 21, 2026, 10:24 PM EDT
Not listed Not applicable Interventional

Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D

NCT02374801
View directory record Official record
Conditions
Heart Failure (NYHA Class III and Ambulatory IV)
Interventions
SonR automatic optimization feature turned ON ("AV+VV").
Device
Lead sponsor
MicroPort CRM
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Jul 21, 2026, 10:24 PM EDT
Completed Early Phase 1 Interventional Results available

Nicotinamide Riboside in LVAD Recipients

NCT03727646
View directory record Official record
Conditions
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
Interventions
Nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jul 21, 2026, 10:24 PM EDT
Not listed Phase 3 Interventional

Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D

NCT01534234
View directory record Official record
Conditions
Heart Failure NYHA Class III and Ambulatory IV
Interventions
PARADYM RF SONR
Device
Lead sponsor
MicroPort CRM
Industry
Eligibility
18 Years and older
Enrollment
1,039 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Culver City, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Jul 21, 2026, 10:24 PM EDT
Withdrawn Not applicable Interventional

Cardiac Rehab for Advanced Heart Failure-LVAD Candidates

NCT03132441
View directory record Official record
Conditions
Heart Failure
Interventions
Strength Training for Frailty
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jul 21, 2026, 10:24 PM EDT
Not listed Phase 4 Interventional

Remission From Stage D Heart Failure

NCT01774656
View directory record Official record
Conditions
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Interventions
Pharmacological Treatment
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 59 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
6
States / cities
Louisville, Kentucky • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 21, 2026, 10:24 PM EDT